Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Stock Short Interest Report for October

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 200 shares, a decline of 71.6% from the September 30th total of 705 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 4,414 shares, the short-interest ratio is currently 0.0 days.

Santen Pharmaceutical Stock Performance

Shares of Santen Pharmaceutical stock opened at $11.01 on Thursday. Santen Pharmaceutical has a 1 year low of $9.22 and a 1 year high of $13.93. The firm’s 50-day simple moving average is $11.18 and its 200-day simple moving average is $11.49.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company focused on ophthalmology. The company researches, develops, manufactures and markets prescription medicines and other products used to diagnose and treat eye diseases.

Its product portfolio includes ophthalmic treatments for conditions such as glaucoma, dry eye, allergic eye disease, ocular infections and retinal disorders. Santen also develops therapies for other vision-related conditions and provides products for eye-care professionals and patients.

Founded in 1890 and headquartered in Osaka, Japan, Santen serves patients and medical professionals through operations and commercial activities in Japan and international markets, including parts of Asia, Europe and other regions.